Xoma reports Xanelim Phase I/II data

XOMA said data from an open-label, 12-week Phase I/II trial showed 46 of 61 (75 percent) patients with moderate to severe psoriasis given Xanelim recombinant humanized anti-CD11a monoclonal antibody had a 50 percent or better improvement in PASI scores at day 84. XOMA also said 19 of 61 patients (31 percent) achieved 75 percent or better improvement. Subcutaneous and intravenous delivery showed similar effects. ...